{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:17:50Z","timestamp":1772745470123,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.bbmt.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T13:08:33Z","timestamp":1425906513000},"page":"1315-1320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study"],"prefix":"10.1016","volume":"21","author":[{"given":"Ahmad-Samer","family":"Al-Homsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelli","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlee","family":"Bogema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Duffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly","family":"Mageed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.02.008_bib1","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1056\/NEJMp078166","article-title":"Hematopoietic cell transplantation at 50","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.02.008_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.25.022106.141606","article-title":"Immunobiology of allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Welniak","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib3","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.bbmt.2011.05.001","article-title":"Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study","volume":"17","author":"Remberger","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation\u2014a report from CIBMTR","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.02.008_bib6","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","article-title":"Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation","volume":"109","author":"Cutler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbmt.2014.08.014","article-title":"Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease","volume":"21","author":"Al-Homsi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib9","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.bbmt.2013.06.019","article-title":"Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation","volume":"19","author":"Ross","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.bbmt.2015.02.008_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/eji.200535298","article-title":"Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells","volume":"36","author":"Nencioni","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1615\/CritRevImmunol.v26.i6.20","article-title":"The proteasome and its inhibitors in immune regulation and immune disorders","volume":"26","author":"Nencioni","year":"2006","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib13","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decrease the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12185-012-1195-6","article-title":"Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3\/CXCL9 expression and induction of apoptosis","volume":"96","author":"Liu","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/bmt.2008.312","article-title":"Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)","volume":"43","author":"Arpinati","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"Nencioni","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3324\/haematol.2008.005017","article-title":"Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T cell population","volume":"94","author":"Blanco","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.02.008_bib18","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2015.02.008_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.exphem.2011.03.001","article-title":"Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells","volume":"39","author":"Tao","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib20","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.transproceed.2013.03.042","article-title":"The protection and therapy effects of bortezomib in murine acute graft-versus-host disease","volume":"45","author":"Li","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2015.02.008_bib21","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/157489206778776925","article-title":"Bortezomib in the treatment of cancer","volume":"1","author":"Roccaro","year":"2006","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.bbmt.2015.02.008_bib23","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1158\/0008-5472.CAN-06-0680","article-title":"Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity","volume":"66","author":"Lundqvist","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2015.02.008_bib24","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.bbmt.2009.10.016","article-title":"Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host-disease?","volume":"16","author":"Storb","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib25","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib26","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib27","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplant cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kankary","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib28","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","article-title":"Calcineurin inhibitor-free graft-versus-host disease prophylaxis with post-transplant cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation","volume":"20","author":"Solomon","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","article-title":"Effects of bortezomib on the immune system: a focus on immune regulation","volume":"19","author":"Mohty","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.02.008_bib30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib31","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.02.008_bib32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.4049\/jimmunol.1203428","article-title":"IL-1\u03b2 and TLR4 signaling are involved in the aggravate murine acute graft-versus-host disease caused by delayed bortezomib administration","volume":"192","author":"Liang","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trim.2013.11.003","article-title":"Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their I\u03baB and NF-\u03baB","volume":"30","author":"Al-Homsi","year":"2013","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.bbmt.2015.02.008_bib34","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1016\/j.bbmt.2013.12.422","article-title":"Nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with end stage renal disease requiring dialysis- a single institution experience","volume":"20","author":"Shadman","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:52:03Z","timestamp":1761058323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1083879115001159"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}